AR086579A1 - Proteinas de union a antigeno - Google Patents
Proteinas de union a antigenoInfo
- Publication number
- AR086579A1 AR086579A1 ARP120101871A ARP120101871A AR086579A1 AR 086579 A1 AR086579 A1 AR 086579A1 AR P120101871 A ARP120101871 A AR P120101871A AR P120101871 A ARP120101871 A AR P120101871A AR 086579 A1 AR086579 A1 AR 086579A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- antigen binding
- antigen
- binding protein
- set forth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Proteínas de unión a antígeno y fragmentos de las mismas que se unen específicamente a Antígeno de Maduración de Linfocitos B (BCMA), particularmente BCMA humano (hBCMA) y que inhiben la unión de BAFF y APRIL con el receptor de BCMA. Se desvelan adicionalmente composiciones farmacéuticas, exploración y procedimientos de tratamientos médico.Reivindicación 3: La proteína de unión a antígeno de la reivindicación 2 en la que el fragmento de unión de antígeno tiene función efectora ADCC potenciada. Reivindicación 7: La proteína de unión a antígeno de acuerdo con la reivindicación 6 comprendiendo adicionalmente la proteína de unión a antígeno una o más de: CDRH1: de SEC ID Nº 1, CDRH2: SEC ID Nº 2, CDRL1: SEC ID Nº 4, CDRL2: SEC ID Nº 5 y/o CDRL3: SEC ID Nº 6. Reivindicación 8: La proteína de unión a antígeno de acuerdo con la reivindicación 7 comprendiendo la proteína de unión a antígeno: i) CDRH3 como se expone en SEC ID Nº 3; ii) CDRH1 como se expone en SEC ID Nº 1; y iii) CDRH2 como se expone en SEC ID Nº 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490732P | 2011-05-27 | 2011-05-27 | |
US201261647196P | 2012-05-15 | 2012-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086579A1 true AR086579A1 (es) | 2014-01-08 |
Family
ID=46148885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101871A AR086579A1 (es) | 2011-05-27 | 2012-05-28 | Proteinas de union a antigeno |
Country Status (37)
Country | Link |
---|---|
US (1) | US20140105915A1 (es) |
EP (4) | EP3693394A1 (es) |
JP (6) | JP6263467B2 (es) |
KR (1) | KR101972446B1 (es) |
CN (2) | CN103562225B (es) |
AR (1) | AR086579A1 (es) |
AU (1) | AU2012264890C1 (es) |
BR (1) | BR112013028779B8 (es) |
CA (1) | CA2833820C (es) |
CL (2) | CL2013003373A1 (es) |
CO (1) | CO6811809A2 (es) |
CR (1) | CR20130624A (es) |
CY (2) | CY2023019I2 (es) |
DK (1) | DK3415531T3 (es) |
DO (1) | DOP2013000280A (es) |
EA (2) | EA201790330A1 (es) |
ES (1) | ES2953190T3 (es) |
FI (2) | FI3415531T3 (es) |
FR (1) | FR23C1032I1 (es) |
HR (1) | HRP20231066T1 (es) |
HU (2) | HUE063461T2 (es) |
IL (2) | IL228784B (es) |
LT (1) | LT3415531T (es) |
MA (1) | MA35208B1 (es) |
MX (1) | MX351069B (es) |
MY (1) | MY177970A (es) |
NL (1) | NL301241I2 (es) |
PE (1) | PE20141045A1 (es) |
PL (1) | PL3415531T3 (es) |
PT (1) | PT3415531T (es) |
RS (1) | RS64791B1 (es) |
SG (1) | SG194176A1 (es) |
SI (1) | SI3415531T1 (es) |
TW (2) | TWI609883B (es) |
UY (1) | UY34101A (es) |
WO (1) | WO2012163805A1 (es) |
ZA (1) | ZA201308635B (es) |
Families Citing this family (200)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1210425B2 (en) | 1999-08-17 | 2015-06-17 | Biogen MA Inc. | Baff receptor (bcma), an immunoregulatory agent |
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
LT3415531T (lt) * | 2011-05-27 | 2023-09-25 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) – surišantys baltymai |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
WO2014068079A1 (en) | 2012-11-01 | 2014-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
EP2762496A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
WO2014122143A1 (en) * | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
EP2762497A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
JP2016507066A (ja) * | 2013-02-08 | 2016-03-07 | インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ | 多発性骨髄腫、慢性リンパ球性白血病、およびb細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
GB2513405A (en) * | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
FI3019240T3 (fi) | 2013-07-09 | 2024-05-30 | Annexon Inc | Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä |
US10435453B2 (en) | 2014-02-07 | 2019-10-08 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
JP6556156B2 (ja) * | 2014-02-27 | 2019-08-07 | ユーシーエル ビジネス ピーエルシー | Aprilバリアント |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
IL248257B1 (en) * | 2014-04-30 | 2024-04-01 | Max Delbruck Centrum Fur Molekulare Medizin In Der Helmholtz Gemeinschaft | Human antibodies against CD269(BCMA) |
WO2015188119A1 (en) | 2014-06-06 | 2015-12-10 | Bluebird Bio, Inc. | Improved t cell compositions |
SG11201700476VA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
AU2015292590B2 (en) | 2014-07-24 | 2020-01-16 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
CN114621969A (zh) | 2014-09-17 | 2022-06-14 | 诺华股份有限公司 | 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞 |
GB201419185D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resin |
CA2966005C (en) | 2014-10-31 | 2021-04-27 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
NZ733025A (en) | 2014-12-12 | 2022-01-28 | 2Seventy Bio Inc | Bcma chimeric antigen receptors |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
CN114149511A (zh) * | 2015-04-13 | 2022-03-08 | 辉瑞公司 | 靶向b细胞成熟抗原的嵌合抗原受体 |
JP6913025B2 (ja) * | 2015-04-13 | 2021-08-04 | ファイザー・インク | 治療抗体およびその使用 |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
EA202092435A3 (ru) * | 2015-08-03 | 2021-06-30 | Энгмаб Сарл | Моноклональные антитела против bcma |
WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
BR112018008799A2 (pt) * | 2015-10-30 | 2019-01-15 | Glaxosmithkline Ip Dev Ltd | método de prognóstico |
EP3374396A1 (en) * | 2015-11-13 | 2018-09-19 | The United States of America, as represented by the secretary, Department of Health and Human Services | Anti-bcma polypeptides and proteins |
EP3380620B1 (en) | 2015-11-23 | 2024-07-03 | Novartis AG | Optimized lentiviral transfer vectors and uses thereof |
IL296130A (en) | 2015-11-24 | 2022-11-01 | Annexon Inc | Anti-complement factor c1q fab fragments and their uses |
SI3380522T1 (sl) | 2015-11-25 | 2024-02-29 | Visterra, Inc. | Molekule protitelesa proti APRIL in uporabe le-teh |
WO2017093942A1 (en) | 2015-12-01 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
BR112018013074A2 (pt) | 2015-12-30 | 2018-12-11 | Novartis Ag | terapias de célula efetora imune com eficácia real-çada |
ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
MX2018009700A (es) * | 2016-02-17 | 2019-01-24 | Seattle Genetics Inc | Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios. |
AU2017225733A1 (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
CA3019135A1 (en) * | 2016-04-01 | 2017-10-05 | Kite Pharma, Inc. | Bcma binding molecules and methods of use thereof |
JP7034934B2 (ja) | 2016-04-01 | 2022-03-14 | カイト ファーマ インコーポレイテッド | キメラ抗原及びt細胞受容体、並びに使用方法 |
KR20230165383A (ko) | 2016-04-01 | 2023-12-05 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
SG11201809041TA (en) | 2016-04-15 | 2018-11-29 | Novartis Ag | Compositions and methods for selective protein expression |
BR112018073739A2 (pt) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
JP7432363B2 (ja) | 2016-06-21 | 2024-02-16 | テネオバイオ, インコーポレイテッド | Cd3結合抗体 |
KR20190036551A (ko) | 2016-08-01 | 2019-04-04 | 노파르티스 아게 | Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료 |
FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
BR112019004711A2 (pt) * | 2016-09-14 | 2019-05-28 | Janssen Biotech Inc | receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos |
WO2018083204A1 (en) | 2016-11-02 | 2018-05-11 | Engmab Sàrl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
EP4215548A1 (en) * | 2016-12-21 | 2023-07-26 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
IL268206B2 (en) | 2017-01-23 | 2024-05-01 | Carsgen Therapeutics Co Ltd | Antibodies directed against BCMA and their use |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
EP3577134A1 (en) | 2017-01-31 | 2019-12-11 | Novartis AG | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
MX2019009552A (es) | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
AU2018228719B2 (en) | 2017-02-28 | 2023-03-30 | Affimed Gmbh | Tandem diabody for CD16A-directed NK-cell engagement |
CN108624549B (zh) * | 2017-03-23 | 2020-11-20 | 上海奥浦迈生物科技有限公司 | 一种cho dg44培养基及其应用 |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
AU2018367896B2 (en) | 2017-05-12 | 2023-06-01 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
CN110740756A (zh) * | 2017-06-14 | 2020-01-31 | 达纳-法伯癌症研究所有限公司 | 针对b细胞成熟抗原(bcma)的纳米颗粒 |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
EP3642237A2 (en) | 2017-06-20 | 2020-04-29 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
JP7240335B2 (ja) | 2017-06-20 | 2023-03-15 | テネオワン, インコーポレイテッド | 抗bcma重鎖のみ抗体 |
BR112020001989A2 (pt) * | 2017-08-01 | 2020-08-18 | Medimmune, Llc | conjugado anticorpo monoclonal contra bcma-fármaco |
CA3075717A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
JP2020533382A (ja) * | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 癌の組合せ治療 |
CN111107874A (zh) | 2017-09-14 | 2020-05-05 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
AU2018341541B2 (en) * | 2017-09-29 | 2021-12-23 | Dana‐Farber Cancer Institute, Inc. | Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same |
EP3694997A4 (en) | 2017-10-12 | 2021-06-30 | Mcmaster University | T-CELL ANTIGEN COUPLER WITH Y182T MUTATION, AND PROCEDURES AND USES THEREOF |
EP3694871A4 (en) | 2017-10-13 | 2021-11-10 | Harpoon Therapeutics, Inc. | B-CELL MATURATION ANTIG-BINDING PROTEINS |
AU2018347582A1 (en) | 2017-10-13 | 2020-05-07 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
JP2021501570A (ja) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
US20220298254A1 (en) | 2017-11-01 | 2022-09-22 | Hummingbird Bioscience Holdings Pte. Ltd. | Cd47 antigen-binding molecules |
GB201720426D0 (en) * | 2017-12-07 | 2018-01-24 | Hummingbird Bioscience Pte Ltd | CD47 and BCMA antigen-binding molecules |
MA50860A (fr) | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants |
TW201922774A (zh) | 2017-11-15 | 2019-06-16 | 瑞士商諾華公司 | 標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法 |
EP3717907A1 (en) | 2017-11-30 | 2020-10-07 | Novartis AG | Bcma-targeting chimeric antigen receptor, and uses thereof |
WO2019133799A1 (en) * | 2017-12-29 | 2019-07-04 | University Of Florida Research Foundation | Monoclonal antibodies targeting microtubule-binding domain of tau protein |
WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
TWI800854B (zh) * | 2018-02-01 | 2023-05-01 | 大陸商信達生物製藥(蘇州)有限公司 | 全人源的抗b細胞成熟抗原(bcma)單鏈抗體及其應用 |
JP6968389B2 (ja) * | 2018-02-01 | 2021-11-17 | 南京馴鹿医療技術有限公司 | Bcmaに結合するキメラ抗原受容体(car)及びその応用 |
EP3752203A1 (en) | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
CA3092037A1 (en) * | 2018-02-21 | 2019-08-29 | Celgene Corporation | Bcma-binding antibodies and uses thereof |
JP7427605B2 (ja) * | 2018-04-05 | 2024-02-05 | ノバルティス アーゲー | 癌に対する三重特異性結合分子及びその使用 |
CN116514995A (zh) * | 2018-04-12 | 2023-08-01 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
RU2022105827A (ru) | 2018-04-13 | 2022-04-05 | Аффимед Гмбх | Слитые конструкции антител для вовлечения nk-клеток |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
BR112020022879A2 (pt) | 2018-05-11 | 2021-02-23 | Crispr Therapeutics Ag | métodos e composições para tratamento de câncer |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
CU20200089A7 (es) | 2018-06-01 | 2021-07-02 | Novartis Ag | Moléculas de unión contra bcma |
WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
SG11202011830SA (en) | 2018-06-13 | 2020-12-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAx抗-CD3抗體及其用途 |
AR114544A1 (es) * | 2018-08-08 | 2020-09-16 | Dragonfly Therapeutics Inc | Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso |
US20220364055A1 (en) | 2018-08-31 | 2022-11-17 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
AU2019346466A1 (en) | 2018-09-25 | 2021-05-20 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
AR116548A1 (es) * | 2018-09-28 | 2021-05-19 | Amgen Inc | Anticuerpos contra bcma soluble |
WO2020073917A1 (en) * | 2018-10-09 | 2020-04-16 | Single Cell Technology, Inc. | Anti-bcma antibodies |
WO2020089794A1 (en) | 2018-10-31 | 2020-05-07 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2020088164A1 (zh) * | 2018-11-01 | 2020-05-07 | 山东新时代药业有限公司 | 双特异性抗体及其用途 |
CN113271945A (zh) | 2018-12-20 | 2021-08-17 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合 |
AU2020214412A1 (en) | 2019-02-01 | 2021-08-12 | Glaxosmithkline Intellectual Property Development Limited | Belantamab mafodotin in combination with pembrolizumab for treating cancer |
EA202192029A1 (ru) | 2019-02-15 | 2021-10-27 | Новартис Аг | Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения |
KR20210129671A (ko) | 2019-02-15 | 2021-10-28 | 노파르티스 아게 | 3-(1-옥소-5-(피페리딘-4-일)이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도 |
SG11202107825WA (en) | 2019-02-25 | 2021-09-29 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
US20230074800A1 (en) | 2019-03-21 | 2023-03-09 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
MX2021014094A (es) | 2019-05-20 | 2022-02-11 | Novartis Ag | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso. |
CN113891731A (zh) * | 2019-05-22 | 2022-01-04 | 小利兰·斯坦福大学理事会 | 药物缀合物及其使用方法 |
CR20210685A (es) * | 2019-05-31 | 2022-05-13 | Medimmune Llc | Terapia de combinación |
CA3140816A1 (en) | 2019-06-14 | 2020-12-17 | Nathan Trinklein | Multispecific heavy chain antibodies binding to cd22 and cd3 |
MX2022001065A (es) | 2019-07-30 | 2022-02-14 | Shanghai Hansoh Biomedical Co Ltd | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. |
KR20220041915A (ko) | 2019-08-06 | 2022-04-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 바이오제약 조성물 및 관련 방법 |
CN112409482B (zh) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | Bcma抗体 |
WO2021068761A1 (zh) | 2019-10-10 | 2021-04-15 | 苏州亲为药业有限公司 | 靶向bcma的具有人猴交叉的人源化单克隆抗体 |
AR120566A1 (es) | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quiméricos y sus usos |
WO2021104371A1 (en) * | 2019-11-26 | 2021-06-03 | Shanghai Epimab Biotherapeutics Co., Ltd. | Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom |
EP4076660A1 (en) | 2019-12-20 | 2022-10-26 | Novartis AG | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
EP4085076A4 (en) * | 2020-01-03 | 2024-01-24 | Biosion, Inc. | ANTIBODIES BINDING TO BCMA AND THEIR USES |
KR20220012314A (ko) * | 2020-01-03 | 2022-02-03 | 살루브리스 (청두) 바이오테크 코., 리미티드 | Bcma에 결합하는 항체 및 그의 용도 |
CN111234020B (zh) * | 2020-01-23 | 2020-10-23 | 和铂医药(苏州)有限公司 | 一种bcma结合蛋白及其制备方法和应用 |
JP2023512023A (ja) | 2020-01-28 | 2023-03-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 併用療法及びその使用及び方法 |
CN113248611A (zh) * | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | 抗bcma抗体、其药物组合物及应用 |
KR20220146530A (ko) | 2020-02-27 | 2022-11-01 | 노파르티스 아게 | 키메라 항원 수용체-발현 세포의 제조 방법 |
CN115397460A (zh) | 2020-02-27 | 2022-11-25 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
CA3182697A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
CN113817056B (zh) * | 2020-06-18 | 2022-11-11 | 重庆精准生物技术有限公司 | 一种靶向cd70的单链抗体及其应用 |
MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
IL300489A (en) | 2020-08-21 | 2023-04-01 | Novartis Ag | Compositions and methods for in vivo production of CAR expressing cells |
US20230374147A1 (en) | 2020-11-02 | 2023-11-23 | Hummingbird Bioscience Pte. Ltd. | Bcma/taci antigen-binding molecules |
IL303048A (en) | 2020-11-24 | 2023-07-01 | Novartis Ag | BCL-XL inhibitor antibody-drug conjugates and methods of using them |
WO2022146891A2 (en) | 2020-12-31 | 2022-07-07 | Sana Biotechnology, Inc. | Methods and compositions for modulating car-t activity |
TW202246351A (zh) * | 2021-02-08 | 2022-12-01 | 美商恩格姆生物製藥公司 | Htra1結合劑及其使用方法 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
EP4330381A1 (en) | 2021-04-27 | 2024-03-06 | Novartis AG | Viral vector production system |
WO2022246293A1 (en) | 2021-05-19 | 2022-11-24 | Sana Biotechnology, Inc. | Hypoimmunogenic rhd negative primary t cells |
CA3216346A1 (en) | 2021-05-27 | 2022-12-01 | Edward Rebar | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
WO2022248870A1 (en) | 2021-05-28 | 2022-12-01 | Glaxosmithkline Intellectual Property Development Limited | Combination therapies for treating cancer |
WO2022256449A1 (en) | 2021-06-01 | 2022-12-08 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 t cell-antigen couplers and uses thereof |
CN115521381A (zh) | 2021-06-24 | 2022-12-27 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
AU2022301302A1 (en) | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
EP4370544A2 (en) | 2021-07-14 | 2024-05-22 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
CN117794954A (zh) | 2021-08-03 | 2024-03-29 | 葛兰素史密斯克莱知识产权发展有限公司 | 生物药物组合物和稳定同位素标记肽图谱方法 |
TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向cd4之病毒載體之用途 |
KR20240053673A (ko) | 2021-08-11 | 2024-04-24 | 사나 바이오테크놀로지, 인크. | 저면역원성 세포 내 유전자 발현을 변경하기 위한 유도성 시스템 |
AR126838A1 (es) | 2021-08-20 | 2023-11-22 | Novartis Ag | Métodos para preparar células que expresan receptores de antígeno quiméricos |
CN118159294A (zh) | 2021-10-05 | 2024-06-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于治疗癌症的联合疗法 |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
CA3236268A1 (en) * | 2021-11-04 | 2023-05-11 | Jens G. LOHR | Developing inducible cluster chimeric antigen receptor (ccar) constructs |
CN118355032A (zh) * | 2021-12-09 | 2024-07-16 | 山东先声生物制药有限公司 | Bcma抗体及其应用 |
TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023144702A1 (en) | 2022-01-25 | 2023-08-03 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy for cancer |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2023232911A1 (en) * | 2022-05-31 | 2023-12-07 | Oncopeptides Innovation 1 Ab | Novel polypeptides |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
WO2024121711A1 (en) | 2022-12-05 | 2024-06-13 | Glaxosmithkline Intellectual Property Development Limited | Methods of treatment using b-cell maturation antigen antagonists |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
WO1997023243A1 (en) | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
CN101371923B (zh) * | 1999-08-17 | 2013-04-17 | 比奥根艾迪克Ma公司 | Baff受体(bcma),一种免疫调节剂 |
EP1210425B2 (en) * | 1999-08-17 | 2015-06-17 | Biogen MA Inc. | Baff receptor (bcma), an immunoregulatory agent |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
US6573074B2 (en) | 2000-04-12 | 2003-06-03 | Smithkline Beecham Plc | Methods for ansamitocin production |
US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
AR030612A1 (es) | 2000-09-12 | 2003-08-27 | Smithkline Beecham Corp | Procedimiento e intermedios |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
EP2301971A1 (en) * | 2001-02-20 | 2011-03-30 | ZymoGenetics, L.L.C. | Antibodies that bind both BCMA and TACI |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
EP2277914A3 (en) | 2001-08-10 | 2012-08-08 | Aberdeen University | Antigen binding domains from fish |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
WO2003072713A2 (en) | 2002-02-21 | 2003-09-04 | Biogen Idec Ma Inc. | Use of bcma as an immunoregulatory agent |
DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
JP4871126B2 (ja) | 2003-07-04 | 2012-02-08 | アフィボディ・アーベー | Her2に対する結合親和性を有するポリペプチド |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
WO2005056764A2 (en) | 2003-12-05 | 2005-06-23 | Compound Therapeutics, Inc. | Inhibitors of type 2 vascular endothelial growth factor receptors |
JP2008505607A (ja) * | 2004-01-29 | 2008-02-28 | ジェネンテック・インコーポレーテッド | Bcmaの細胞外ドメインの変異体とその使用法 |
EP1776385A1 (en) | 2004-07-21 | 2007-04-25 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
US7947805B2 (en) * | 2004-12-23 | 2011-05-24 | Merck Serono S.A. | BCMA polypeptides and uses thereof |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
EP1921090B1 (en) | 2005-07-22 | 2015-01-14 | Kyowa Hakko Kirin Co., Ltd. | Genetically modified antibody composition |
CN101490088B (zh) * | 2006-06-22 | 2015-04-08 | 健泰科生物技术公司 | 用于靶向hepsin的方法和组合物 |
EA017733B1 (ru) * | 2006-08-28 | 2013-02-28 | Арес Трейдинг С.А. | СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
KR20100097737A (ko) * | 2008-01-15 | 2010-09-03 | 에프. 호프만-라 로슈 아게 | Ccr5에 대한 어푸코실화된 항체 및 이의 용도 |
HUE029619T4 (en) * | 2009-03-10 | 2017-07-28 | Biogen Ma Inc | Anti-bcma antibodies |
WO2011108008A2 (en) * | 2010-03-04 | 2011-09-09 | Transgene Biotek Ltd. | Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1 |
EP3974453A3 (en) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
LT3415531T (lt) | 2011-05-27 | 2023-09-25 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) – surišantys baltymai |
UA112434C2 (uk) * | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
-
2012
- 2012-05-24 LT LTEP18163942.8T patent/LT3415531T/lt unknown
- 2012-05-24 EA EA201790330A patent/EA201790330A1/ru unknown
- 2012-05-24 MY MYPI2013702251A patent/MY177970A/en unknown
- 2012-05-24 PE PE2013002545A patent/PE20141045A1/es active IP Right Grant
- 2012-05-24 SI SI201232040T patent/SI3415531T1/sl unknown
- 2012-05-24 BR BR112013028779A patent/BR112013028779B8/pt active IP Right Grant
- 2012-05-24 CA CA2833820A patent/CA2833820C/en active Active
- 2012-05-24 JP JP2014511888A patent/JP6263467B2/ja active Active
- 2012-05-24 KR KR1020137034803A patent/KR101972446B1/ko active IP Right Grant
- 2012-05-24 EP EP20153215.7A patent/EP3693394A1/en not_active Withdrawn
- 2012-05-24 CN CN201280025793.1A patent/CN103562225B/zh active Active
- 2012-05-24 WO PCT/EP2012/059762 patent/WO2012163805A1/en active Application Filing
- 2012-05-24 SG SG2013076138A patent/SG194176A1/en unknown
- 2012-05-24 RS RS20231039A patent/RS64791B1/sr unknown
- 2012-05-24 FI FIEP18163942.8T patent/FI3415531T3/fi active
- 2012-05-24 HR HRP20231066TT patent/HRP20231066T1/hr unknown
- 2012-05-24 EP EP23183917.6A patent/EP4338754A3/en active Pending
- 2012-05-24 US US14/122,391 patent/US20140105915A1/en not_active Abandoned
- 2012-05-24 EA EA201391457A patent/EA028220B1/ru not_active IP Right Cessation
- 2012-05-24 EP EP12723206.4A patent/EP2714737A1/en not_active Withdrawn
- 2012-05-24 PT PT181639428T patent/PT3415531T/pt unknown
- 2012-05-24 EP EP18163942.8A patent/EP3415531B1/en active Active
- 2012-05-24 CN CN201610808775.0A patent/CN106279418A/zh active Pending
- 2012-05-24 PL PL18163942.8T patent/PL3415531T3/pl unknown
- 2012-05-24 HU HUE18163942A patent/HUE063461T2/hu unknown
- 2012-05-24 AU AU2012264890A patent/AU2012264890C1/en active Active
- 2012-05-24 DK DK18163942.8T patent/DK3415531T3/da active
- 2012-05-24 ES ES18163942T patent/ES2953190T3/es active Active
- 2012-05-24 MX MX2013013942A patent/MX351069B/es active IP Right Grant
- 2012-05-25 UY UY0001034101A patent/UY34101A/es not_active Application Discontinuation
- 2012-05-25 TW TW101118855A patent/TWI609883B/zh active
- 2012-05-25 TW TW106128318A patent/TWI644924B/zh active
- 2012-05-28 AR ARP120101871A patent/AR086579A1/es active IP Right Grant
-
2013
- 2013-10-08 IL IL228784A patent/IL228784B/en active IP Right Grant
- 2013-11-18 ZA ZA2013/08635A patent/ZA201308635B/en unknown
- 2013-11-19 CO CO13271946A patent/CO6811809A2/es active IP Right Grant
- 2013-11-25 CL CL2013003373A patent/CL2013003373A1/es unknown
- 2013-11-26 DO DO2013000280A patent/DOP2013000280A/es unknown
- 2013-11-27 CR CR20130624A patent/CR20130624A/es unknown
- 2013-12-25 MA MA36613A patent/MA35208B1/fr unknown
-
2016
- 2016-10-12 CL CL2016002585A patent/CL2016002585A1/es unknown
-
2017
- 2017-10-25 IL IL255253A patent/IL255253A0/en unknown
- 2017-12-18 JP JP2017241606A patent/JP2018087190A/ja active Pending
-
2019
- 2019-04-22 JP JP2019080646A patent/JP7018910B2/ja active Active
-
2021
- 2021-11-19 JP JP2021188586A patent/JP7260621B2/ja active Active
-
2023
- 2023-04-06 JP JP2023062129A patent/JP7475515B2/ja active Active
- 2023-09-07 NL NL301241C patent/NL301241I2/nl unknown
- 2023-09-07 FR FR23C1032C patent/FR23C1032I1/fr active Active
- 2023-09-07 CY CY2023019C patent/CY2023019I2/el unknown
- 2023-09-07 FI FIC20230029C patent/FIC20230029I1/fi unknown
- 2023-09-07 CY CY20231100477T patent/CY1126300T1/el unknown
- 2023-10-27 HU HUS2300027C patent/HUS2300027I1/hu unknown
-
2024
- 2024-04-16 JP JP2024066216A patent/JP2024096908A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR123305A2 (es) | Proteínas de unión a antígeno | |
AR086579A1 (es) | Proteinas de union a antigeno | |
AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
PE20191131A1 (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos | |
PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
PE20170687A1 (es) | Proteinas de enlace a cd127 | |
PE20180120A1 (es) | Proteinas de union a icos | |
ES2631135T3 (es) | Proteínas de unión a antígeno humanas que se unen a beta-Klotho, receptores de FGF y complejos de los mismos | |
PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
JP2020500538A5 (es) | ||
PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
PE20140133A1 (es) | Nuevas proteinas de union a antigenos | |
PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
AR081556A1 (es) | Proteinas de union al antigeno humanizadas | |
AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
AR073770A1 (es) | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden | |
PE20090768A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
NZ596274A (en) | Blocking anti-dkk-1 antibodies and their uses | |
AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
RS52345B (en) | ANTI-IL-23P19 ANTIBODY MANUFACTURED BY GENETIC ENGINEERING | |
PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |